FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381683648> ?p ?o ?g. }

• W4381683648 abstract "Abstract Study question Can similar mean follitropin delta daily/total doses yield satisfactory ICSI outcomes in different subgroups of maternal age and body mass index (BMI)? Summary answer Similar mean follitropin delta daily/total doses yield satisfactory number of oocytes and maturity rates, and pregnancy rates in different subgroups of maternal age and BMI. What is known already Rekovelle® (follitropin delta) is a novel recombinant human FSH (rFSH) expressed from a host cell line of human fetal retinal origin (PER.C6®) and is the first commercially available rFSH product derived from human cell lines. Rekovelle® allows the individualization of the initial dose of gonadotropin using predictive response factors to COS, such as anti-müllerian hormone (AMH) levels and body weight. In clinical practice different approaches can be adopted to obtain the most satisfactory response to controlled ovarian stimulation (COS). The objective of this study was to describe data on “real-world” Rekovelle® administration, regarding the response to COS and ICSI outcomes. Study design, size, duration This non-interventional study based on secondary use of data included patients undergoing ICSI in a private university-affiliated IVF center from Jan/2018 to Dec/2021. Each patient or cycle had to meet the following inclusion criteria: pre-menopausal women, undergoing COS with Rekovelle® (16 ug) daily for ICSI; diagnosed with infertility, or with partners diagnosed with male infertility factors, eligible for ICSI using fresh sperm from partner ejaculation; presenting with both ovaries. Participants/materials, setting, methods Ovarian response to stimulation and ICSI outcomes were described for 362 ICSI cycles. The primary outcome measures were the numbers of retrieved oocytes and maturity rates, and the secondary outcome were the ongoing pregnancy rates per fresh and per fresh and/or frozen-thawed embryo transfer. The results obtained with the population enrolled in the ESTHER-1 trial (extern), and a population stimulated with follitropin alpha 300 IU (on site) were recorded (data not shown, to be presented). Main results and the role of chance The mean total dose of follitropin delta administered in subgroups of age and BMI were as follows: age ≤35 y-old 156µg, 36-39 y-old 158 µg, and ≥40 y-old 157µg, and BMI: &lt;18.5 165µg, 18.5-24.9 156µg, 25.0-24.9 159µg, and ≥30 171µg. Patients in the Follitropin delta group showed acceptable outcomes in different age and BMI groups (Table1). Adequate embryo morphokinetic development and euploidy rates were also observed, suggesting that the modified protocol does not interfere with oocyte/embryo competences and embryo implantation potential. This was further corroborated by satisfactory cumulative pregnancy rates. Limitations, reasons for caution Given its descriptive nature, we have focused on the number and maturity stage of retrieved oocytes instead of clinical ICSI outcomes. The use of historical cohort groups is another drawback. Despite the eligibility criteria for inclusion in the analysis, potential differences in the baseline characteristics cannot be ruled out. Wider implications of the findings Patients in different subgroups of age and BMI stimulated with similar mean follitropin delta daily and total doses showed satisfactory number of retrieved oocytes and maturity rates, and cumulative pregnancy rates without increasing OHSS, providing a rationale for conducting clinical trials to confirm the benefits of using this modified protocol. Trial registration number N/A" @default.
• W4381683648 created "2023-06-23" @default.
• W4381683648 creator A5030261811 @default.
• W4381683648 creator A5042875708 @default.
• W4381683648 creator A5051939732 @default.
• W4381683648 creator A5057580627 @default.
• W4381683648 creator A5090976681 @default.
• W4381683648 date "2023-06-01" @default.
• W4381683648 modified "2023-10-16" @default.
• W4381683648 title "P-590 Similar mean follitropin delta daily/total doses yield satisfactory ICSI outcomes in different subgroups of maternal age and body mass index: a “real-world” experience with Rekovelle®" @default.
• W4381683648 doi "https://doi.org/10.1093/humrep/dead093.920" @default.
• W4381683648 hasPublicationYear "2023" @default.
• W4381683648 type Work @default.
• W4381683648 citedByCount "0" @default.
• W4381683648 crossrefType "journal-article" @default.
• W4381683648 hasAuthorship W4381683648A5030261811 @default.
• W4381683648 hasAuthorship W4381683648A5042875708 @default.
• W4381683648 hasAuthorship W4381683648A5051939732 @default.
• W4381683648 hasAuthorship W4381683648A5057580627 @default.
• W4381683648 hasAuthorship W4381683648A5090976681 @default.
• W4381683648 hasConcept C126322002 @default.
• W4381683648 hasConcept C131872663 @default.
• W4381683648 hasConcept C2776537878 @default.
• W4381683648 hasConcept C2777688143 @default.
• W4381683648 hasConcept C2778782382 @default.
• W4381683648 hasConcept C2779234561 @default.
• W4381683648 hasConcept C2780221984 @default.
• W4381683648 hasConcept C29456083 @default.
• W4381683648 hasConcept C54355233 @default.
• W4381683648 hasConcept C71315377 @default.
• W4381683648 hasConcept C71924100 @default.
• W4381683648 hasConcept C86803240 @default.
• W4381683648 hasConceptScore W4381683648C126322002 @default.
• W4381683648 hasConceptScore W4381683648C131872663 @default.
• W4381683648 hasConceptScore W4381683648C2776537878 @default.
• W4381683648 hasConceptScore W4381683648C2777688143 @default.
• W4381683648 hasConceptScore W4381683648C2778782382 @default.
• W4381683648 hasConceptScore W4381683648C2779234561 @default.
• W4381683648 hasConceptScore W4381683648C2780221984 @default.
• W4381683648 hasConceptScore W4381683648C29456083 @default.
• W4381683648 hasConceptScore W4381683648C54355233 @default.
• W4381683648 hasConceptScore W4381683648C71315377 @default.
• W4381683648 hasConceptScore W4381683648C71924100 @default.
• W4381683648 hasConceptScore W4381683648C86803240 @default.
• W4381683648 hasIssue "Supplement_1" @default.
• W4381683648 hasLocation W43816836481 @default.
• W4381683648 hasOpenAccess W4381683648 @default.
• W4381683648 hasPrimaryLocation W43816836481 @default.
• W4381683648 hasRelatedWork W1987941675 @default.
• W4381683648 hasRelatedWork W2086998062 @default.
• W4381683648 hasRelatedWork W2176924341 @default.
• W4381683648 hasRelatedWork W2282629949 @default.
• W4381683648 hasRelatedWork W2354196208 @default.
• W4381683648 hasRelatedWork W2367560744 @default.
• W4381683648 hasRelatedWork W2917628698 @default.
• W4381683648 hasRelatedWork W3032599493 @default.
• W4381683648 hasRelatedWork W3134682017 @default.
• W4381683648 hasRelatedWork W4310493648 @default.
• W4381683648 hasVolume "38" @default.
• W4381683648 isParatext "false" @default.
• W4381683648 isRetracted "false" @default.
• W4381683648 workType "article" @default.